| Shi, yuankai |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
GPS, NCT05219162: Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(). |
|
|
| Completed | 4 | 182 | RoW | Gene Profile explore | AstraZeneca | Advanced NSCLC | 05/24 | 05/24 | | |
NCT03650933: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients |
|
|
| Recruiting | 3 | 360 | RoW | G-CHOP, R-CHOP | Nanjing Yoko Biomedical Co., Ltd. | Diffuse Large B-Cell Lymphoma, Unspecified Site | 08/22 | 12/25 | | |
INSPIRE, NCT04632758: Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients |
|
|
| Active, not recruiting | 3 | 292 | RoW | WX-0593 Tablets, FL-006, crizotinib | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/24 | 12/24 | | |
NCT04416035: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC |
|
|
| Recruiting | 3 | 608 | RoW | TRS003, China-approved Bevacizumab, Carboplatin, Paclitaxel | Zhejiang Teruisi Pharmaceutical Inc. | Advanced Non-squamous Non-small-cell Lung Cancer | 10/21 | 11/21 | | |
NCT05318443: A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer |
|
|
| Completed | 3 | 512 | RoW | SIBP04, Avastin, Paclitaxel, Carboplatin | Shanghai Institute Of Biological Products, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non-squamous Non-small-cell Lung Cancer | 12/22 | 01/23 | | |
ORIENT-3, NCT03150875: A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC |
|
|
| Completed | 3 | 290 | RoW | IBI308, Docetaxel | Innovent Biologics (Suzhou) Co. Ltd. | Non-small Cell Lung Cancer | 02/23 | 02/23 | | |
|
NCT04143607: ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC |
|
|
| Active, not recruiting | 3 | 337 | RoW | ASK120067, Placebo Gefitinib 250 mg, Placebo Iressa 250 mg, Gefitinib, Placebo ASK120067 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic NSCLC | 03/24 | 09/26 | | |
NCT04044222: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy |
|
|
| Recruiting | 3 | 240 | RoW | Sintilimab, Carboplatin, Etoposide, Ifosfamide, Placebo | Innovent Biologics (Suzhou) Co. Ltd. | Classic Hodgkin's Lymphoma | 07/23 | 12/24 | | |
HLX10-002-NSCLC301, NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 643 | RoW | HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed | Shanghai Henlius Biotech | Carcinoma, Non-Small-Cell Lung | 10/23 | 03/24 | | |
TQB2450-Ⅲ-11, NCT05346952: A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). |
|
|
| Recruiting | 3 | 390 | RoW | TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Non-squamous Non-small Cell Lung Cancer | 12/23 | 12/23 | | |
NCT03866499: A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients |
|
|
| Active, not recruiting | 3 | 369 | RoW | BPI-7711, BPI-7711 capsule, Gefitinib, Iressa, Placebo Tablet, placebo, Placebo capsule | Beta Pharma Shanghai | NSCLC | 11/23 | 12/25 | | |
NCT04834024: MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma |
|
|
| Recruiting | 3 | 168 | RoW | Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide | Beijing Mabworks Biotech Co., Ltd. | Follicular Lymphoma and Marginal Zone Lymphoma | 03/25 | 03/25 | | |
NCT06128837: Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 686 | RoW | Irinotecan hydrochloride liposome Injection, Topotecan | Luye Pharma Group Ltd. | Relapsed Small Cell Lung Cancer | 06/28 | 10/28 | | |
NCT04830813: Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer |
|
|
| Recruiting | 3 | 180 | RoW | Chiauranib, CS2164, Placebo, Simulation tablet of Chiauranib | Chipscreen Biosciences, Ltd. | Small Cell Lung Cancer | 12/24 | 12/24 | | |
| Not yet recruiting | 3 | 255 | RoW | SY-3505 Capsules, CT-3505; Ficonalkib, Crizotinib Capsules, Xalkori | Shouyao Holdings (Beijing) Co. LTD | Non-small Cell Lung Cancer | 05/26 | 05/27 | | |
NCT05294172: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 295 | RoW | KL-A167, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin injection, Placebo | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma, Recurrent or Metastatic | 05/24 | 05/25 | | |
TQB2450-III-12, NCT05718167: TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. |
|
|
| Not yet recruiting | 3 | 570 | RoW | TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Squamous Non-Small Cell Lung Carcinoma | 10/24 | 10/25 | | |
NCT06658353: Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors |
|
|
| Not yet recruiting | 3 | 54 | RoW | VC004 Capsules | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor | 12/26 | 12/26 | | |
NCT04874844: JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety |
|
|
| Not yet recruiting | 2/3 | 420 | NA | Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025) | Beijing Dongfang Biotech Co., Ltd., Chinese Academy of Medical Sciences | NSCLC | 03/22 | 06/23 | | |
INTELLECT, NCT04641754: A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 176 | RoW | WX-0593 Tablets, FL-006 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/20 | 03/21 | | |
TQB2450-II-01, NCT03800706: A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 85 | RoW | TQB2450 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Safety and Effectiveness | 06/21 | 12/21 | | |
NCT03502629: Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) |
|
|
| Recruiting | 2 | 86 | RoW | GB226, Recombinant humanized anti-PD-1 monoclonal antibody injection, Geptanolimab | Genor Biopharma Co., Ltd. | Peripheral T Cell Lymphoma | 08/21 | 12/22 | | |
NCT03623581: Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) |
|
|
| Recruiting | 2 | 35 | RoW | GB226, Recombinant humanized anti-PD-1 monoclonal antibody injection, Geptanolimab | Genor Biopharma Co., Ltd. | Alveolar Soft Part Sarcoma | 08/21 | 12/22 | | |
| Recruiting | 2 | 53 | RoW | GB226, Geptanolimab Injection | Genor Biopharma Co., Ltd. | B-cell Non-Hodgkin's Lymphoma | 09/21 | 12/22 | | |
NCT04610970: A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL） |
|
|
| Recruiting | 2 | 93 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 03/22 | 06/22 | | |
NCT04994626: Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies |
|
|
| Not yet recruiting | 2 | 20 | NA | Ibrutinib Combined With Rituximab, Imbruvica Combined With Rituximab | Chinese Academy of Medical Sciences | DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation, CD79B Gene Mutation, Relapse, Refractory Lymphoma | 04/22 | 07/25 | | |
NCT04574817: Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) |
|
|
| Not yet recruiting | 2 | 66 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Anaplastic Thyroid Cancer | 05/22 | 05/23 | | |
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 69 | RoW | LP002 | Taizhou HoudeAoke Biomedical Co., Ltd. | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | 05/22 | 05/23 | | |
NCT04838548: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 90 | RoW | MRG003 | Shanghai Miracogen Inc. | Carcinoma, Non-Small-Cell Lung | 12/22 | 02/23 | | |
NCT04620837: Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy |
|
|
| Recruiting | 2 | 25 | RoW | Tislelizumab, Anlotinib hydrochloride, Anlotinib | Chinese Academy of Medical Sciences | Small Cell Lung Carcinoma | 12/22 | 12/23 | | |
NCT04827004: A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Diffuse Large B-cell Lymphoma | 12/22 | 12/22 | | |
NCT04999800: Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 |
|
|
| Recruiting | 2 | 20 | RoW | Pembrolizumab, Keytruda, Anlotinib, AL3818 | Shi Yuankai | Head and Neck Squamous Cell Carcinoma | 01/23 | 06/24 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT04381910: Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer |
|
|
| Completed | 2 | 66 | RoW | LY01610( Irinotecan hydrochloride liposome injection ) | Luye Pharma Group Ltd. | Small Cell Lung Cancer | 03/23 | 03/23 | | |
NCT06074107: Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects |
|
|
| Active, not recruiting | 2 | 128 | RoW | BEBT-908 for injection, CUDC-908 | BeBetter Med Inc | Relapsed or Refractory Diffuse Large B-cell Lymphoma | 12/23 | 12/23 | | |
NCT04000737: YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 125 | US, RoW | YIV-906+Sorafenib, Placebo+Sorafenib | Yiviva Inc. | Advanced Hepatocellular Carcinoma | 12/23 | 05/24 | | |
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 88 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer | 06/26 | 12/26 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
NCT12345, NCT04857164: Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China |
|
|
| Completed | 2 | 67 | RoW | Pembrolizumab combined with Chemotherapy, keytruda and Chemotherapy | Yuankai Shi | Head and Neck Squamous Cell Carcinoma | 08/23 | 03/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05146219: Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation |
|
|
| Active, not recruiting | 2 | 60 | RoW | TY-9591 Tablets, TY-9591 | TYK Medicines, Inc | NSCLC, EGFR Activating Mutation, Brain Metastases, Leptomeningeal Metastasis | 06/24 | 12/24 | | |
NCT05741021: A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Not yet recruiting | 2 | 84 | RoW | F520, Rulonilimab, Pemetrexed, Carboplatin, Paclitaxel | Shandong New Time Pharmaceutical Co., LTD | Non-small Cell Lung Cancer, NSCLC, PD-1 | 10/24 | 10/24 | | |
NCT04824079: Keynatinib in Treated Patients With NSCLC and Brain Metastases |
|
|
| Recruiting | 2 | 30 | RoW | Keynatinib, TL007 | Medolution Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases | 04/25 | 07/25 | | |
NCT05869162: Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI |
|
|
| Recruiting | 2 | 153 | RoW | SY-3505, CT-3505 | Shouyao Holdings (Beijing) Co. LTD | Non-small-cell Lung Carcinoma | 06/25 | 06/25 | | |
NCT05948813: TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases |
|
|
| Recruiting | 2 | 420 | RoW | TY-9591, Osimertinib, Tagrisso | TYK Medicines, Inc | NSCLC, EGFR Activating Mutation, Brain Metastases | 06/25 | 12/27 | | |
NCT05900219: Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 75 | NA | HL-085+Vemurafenib | Shanghai Kechow Pharma, Inc. | Non-small-cell Lung Cancer | 09/25 | 09/25 | | |
NCT04110301: MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) |
|
|
| Recruiting | 1b/2 | 53 | RoW | Recombinant Humanized Monoclonal Antibody MIL62 Injection, MIL62, Lenalidomide, Revlimid | Beijing Mabworks Biotech Co., Ltd. | Follicular Lymphoma and Marginal Zone Lymphoma | 05/24 | 05/25 | | |
NCT04622072: XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Terminated | 1/2 | 21 | RoW | XZP-5809-TT1 Tablet | Sihuan Pharmaceutical Holdings Group Ltd. | Non Small Cell Lung Cancer | 05/21 | 04/22 | | |
NCT03639467: Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 1/2 | 40 | RoW | Anlotinib plus gemcitabine/cisplatin | Chinese Academy of Medical Sciences | Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma | 08/21 | 08/23 | | |
NCT02698111: Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma |
|
|
| Terminated | 1/2 | 20 | RoW | Donafenib, CM4307 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Nasopharyngeal Carcinoma | 10/21 | 10/21 | | |
NCT03565003: A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China |
|
|
| Completed | 1/2 | 126 | RoW | JAB-3068 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors | 01/23 | 01/23 | | |
NCT05189093: Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 1/2 | 99 | RoW | Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection | Hangzhou Hanx Biopharmaceuticals, Ltd. | Relapsed/Refractory Lymphoma | 12/25 | 12/26 | | |
NCT04024696: A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients |
|
|
| Active, not recruiting | 1/2 | 12 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc., Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non Hodgkin Lymphoma | 02/24 | 06/24 | | |
NCT04175847: A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | RC88, RC88 for Injection | RemeGen Co., Ltd. | Solid Tumor | 09/24 | 09/25 | | |
NCT05257512: Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 150 | RoW | SY-3505, CT-3505 | Shouyao Holdings (Beijing) Co. LTD | Non-small Cell Lung Cancer | 04/24 | 08/24 | | |
NCT04458389: A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas |
|
|
| Recruiting | 1/2 | 268 | RoW | TY101 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Locally Advanced /Metastatic Solid Tumors, Relapsed or Refractory Lymphomas | 06/24 | 07/25 | | |
NCT06581419: A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors |
|
|
| Not yet recruiting | 1/2 | 78 | RoW | IAP0971 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Neoplasm, Advanced or Metastatic Non-small Cell Lung Cancer | 08/29 | 08/29 | | |
NCT05434299: A Study of TFX05-01 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 36 | RoW | TFX05-01 | Shenzhen Yangli Pharmaceutical Technology Co., Ltd | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT05804526: A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 82 | RoW | RC88, Sintilimab Injection, Sintilimab | RemeGen Co., Ltd. | Advanced Solid Tumours | 05/25 | 12/25 | | |
NCT05805943: Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 154 | RoW | IMM0306 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | CD20-positive B-cell Non-Hodgkin's Lymphoma | 05/25 | 05/25 | | |
NCT04996121: A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 360 | RoW | XZP-5955 tablets | Xuanzhu Biopharmaceutical Co., Ltd. | Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic Non-small Cell Lung Cancer | 09/25 | 06/27 | | |
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC |
|
|
| Recruiting | 1/2 | 106 | RoW | RC108, Furmonertinib, Toripalimab | RemeGen Co., Ltd. | NSCLC | 09/25 | 09/26 | | |
NCT04304040: A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma |
|
|
| Active, not recruiting | 1/2 | 43 | RoW | Orelabrutinib, Recombinant humanized monoclonal antibody MIL62 injection | Beijing InnoCare Pharma Tech Co., Ltd. | B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | 12/25 | 12/25 | | |
NCT03374007: Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma |
|
|
| Recruiting | 1 | 72 | RoW | Geptanolimab Injection 1mg/kg, Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg, Geptanolimab Injection 1mg/kg, q2w*6, Geptanolimab Injection 3mg/kg, q2w*6, Geptanolimab Injection 10mg/kg, , q2w*6, Geptanolimab Injection 280mg, q3w, Geptanolimab Injection 3mg/kg, q2w | Genor Biopharma Co., Ltd. | Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma | 06/22 | 08/22 | | |
NCT04093466: A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 126 | RoW | CX1003, kanitinib | Beijing Konruns Pharmaceutical Co., Ltd., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, West China Hospital, Beijing Tongren Hospital | Advanced Solid Tumor | 10/25 | 12/25 | | |
NCT04058587: A Phase I Trial of Simmitinib in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | Simmitinib, SOMCL-15-290 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd | Advanced Solid Tumor | 01/23 | 03/23 | | |
NCT06565689: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012 |
|
|
| Recruiting | 1 | 48 | RoW | YK012, YK012 for Injection | Excyte Biopharma Ltd | Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | 06/26 | 12/26 | | |
NCT06410092: Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001 |
|
|
| Recruiting | 1 | 44 | RoW | FTL001 | Sound Biopharmaceuticals Ltd. | Solid Tumor | 01/26 | 03/27 | | |
NCT03781219: A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 45 | RoW | HL-085, Vemurafenib, ZELBORAF | Shanghai Kechow Pharma, Inc. | Solid Tumor | 12/23 | 12/23 | | |
NCT04121286: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China |
|
|
| Recruiting | 1 | 24 | RoW | JAB-3312 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors | 12/23 | 12/23 | | |
NCT04977167: Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma |
|
|
| Recruiting | 1 | 96 | RoW | HG146, PD-(L)1 antibody | HitGen Inc. | Solid Tumor, Lymphoma | 12/24 | 12/24 | | |
NCT06164327: Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 1 | 75 | RoW | BEBT-908 for Injection, CUDC-908, Rituximab Injection, IDEC-C2B8, Gemcitabine Hydrochloride for Injection, NSC 613327, Oxaliplatin Injection, NSC 266046, Etoposide Injection, VP-16213, Ifosfamide for Injection, NSC109724, Carboplatin Injection, NSC 241240 | BeBetter Med Inc | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 10/25 | 11/25 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/24 | 12/24 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05341557: A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma |
|
|
| Not yet recruiting | 1 | 110 | RoW | BPI-371153 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor, Lymphoma, NSCLC, HCC | 06/24 | 06/25 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT04617314: A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 32 | RoW | RC108, RC108 for injection | RemeGen Co., Ltd. | Solid Tumor | 05/25 | 12/25 | | |
NCT06037317: A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors |
|
|
| Recruiting | 1 | 38 | RoW | SY-3505, CT-3505, Ficonalkib | Shouyao Holdings (Beijing) Co. LTD | Advanced Solid Tumor | 12/25 | 05/26 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
| Recruiting | 1 | 75 | RoW | Keynatinib, TL007 | Medolution Ltd. | Lymphoma, B-Cell | 10/27 | 04/28 | | |
NCT04740996: Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China |
|
|
| Recruiting | N/A | 30 | RoW | Pembrolizumab, keytruda | Shi Yuankai | Head and Neck Squamous Cell Carcinoma | 02/24 | 02/24 | | |
NCT04491721: Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL |
|
|
| Enrolling by invitation | N/A | 407 | RoW | | Chinese Academy of Medical Sciences | Diffuse Large B Cell Lymphoma | 06/27 | 07/27 | | |
| Shi, Yankai |
HLX10-002-NSCLC301, NCT03952403: A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 643 | RoW | HLX10, an engineered anti-PD-1 antibody, HLX04, a bevacizumab biosimilar, Carboplatin, Pemetrexed | Shanghai Henlius Biotech | Carcinoma, Non-Small-Cell Lung | 10/23 | 03/24 | | |
